News Sofinnova closes new fund and backs a trio of new biotechs Sofinnova Partners has raised €165m for its new biotech fund and backed three startups working on Alzheimer's, fibrotic diseases, and cell therapies.
News Andexxa reaches the end of the line in the US AstraZeneca will voluntarily take its anticoagulant reversal agent Andexxa off the market in the US amid reports of serious clotting side effects.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.